Literature DB >> 7005550

Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass.

D Coppe, M Sobel, L Seamans, F Levine, E Salzman.   

Abstract

Thirty-four dogs underwent total cardiopulmonary bypass for 1 or 2 hours with a bubble oxygenator and cardiotomy suction. The dogs were divided into three groups: control dogs which received heparin alone, dogs which received prostacyclin (PGI2) and heparin, and dogs which received prostacyclin alone. PGI2 was given as a bolus (6 to 60 microgram) and then as a constant infusion (0.2 to 0.8 microgram/kg/min) in the venous outflow line. The pump flows were equal in the three groups. PGI2 as a bolus led to transient hypotension, and 60 microgram reduced cardiac output temporarily. During cardiopulmonary bypass, dogs treated with prostacyclin and heparin had low mean arterial perfusion pressures which responded to fluid infusion or phenylephrine. After 1 hour of cardiopulmonary bypass and reversal with protamine, dogs treated with prostacyclin and heparin had shorter bleeding times (p < 0.02) and better platelet function than control animals. After 2 hours, they had normal platelet number, but only half showed preservation of platelet function. When heparin was omitted, PGI2 preserved platelet number, but consumption coagulopathy developed, with prolonged prothrombin, partial thromboplastin, and bleeding times and decreased fibrinogen levels. PGI 2 preserves platelet number and function but may cause hypotension, and it cannot replace heparin in cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7005550

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  3 in total

1.  Phosphodiesterase-inhibitors enoximone and piroximone in cardiac surgery: influence on platelet count and function.

Authors:  J Boldt; C Knothe; B Zickmann; C Herold; E Dapper; G Hempelmann
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

2.  A prospective study of the clinical benefits of prostacyclin in 554 cardiopulmonary bypass procedures.

Authors:  M Merli; B Amari; C Cattani; L Villa; M M Visigalli; A Pellegrini
Journal:  Tex Heart Inst J       Date:  1988

Review 3.  Role of platelet inhibitor therapy in myocardial infarction.

Authors:  B Stein; V Fuster
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.